Cargando…
In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay
BACKGROUND: Homologous recombination repair (HRR) is the main mechanism of repair of DNA double-strand breaks. Its deficiency (HRD) is a common feature of epithelial ovarian cancers (EOCs). BRCA1/2 mutations and/or other aberrations in genes of HRR are well known causes of HRD and genomic instabilit...
Autores principales: | Fumagalli, Caterina, Betella, Ilaria, Ranghiero, Alberto, Guerini-Rocco, Elena, Bonaldo, Giulio, Rappa, Alessandra, Vacirca, Davide, Colombo, Nicoletta, Barberis, Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Pacini Editore srl
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624133/ https://www.ncbi.nlm.nih.gov/pubmed/36136896 http://dx.doi.org/10.32074/1591-951X-791 |
Ejemplares similares
-
Implementing HRD technology /
Publicado: (1999) -
Cryo-EM structure of the protein-conducting ERAD channel Hrd1 in complex with Hrd3
por: Schoebel, Stefan, et al.
Publicado: (2017) -
Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!
por: Magliacane, Gilda, et al.
Publicado: (2022) -
HRD Testing of Ovarian Cancer in Routine Practice: What Are We Dealing With?
por: Kekeeva, Tatiana, et al.
Publicado: (2023) -
Endoplasmic Reticulum Degradation Requires Lumen to Cytosol Signaling: Transmembrane Control of Hrd1p by Hrd3p
por: Gardner, Richard G., et al.
Publicado: (2000)